Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints
03/06/2026 24:06
BRIEF-Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints June 2 (Reuters) - Zenas Biopharma Inc ZBIO.O:
ZENAS BIOPHARMA ANNOUNCES DATA FROM THE REGISTRATIONAL PHASE 3 INDIGO TRIAL OF OBEXELIMAB IN IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD), SIMULTANEOUSLY PRESENTED AT THE EULAR 2026 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
ZENAS BIOPHARMA - PHASE 3 INDIGO TRIAL OF OBEXELIMAB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS
ZENAS BIOPHARMA - OBEXELIMAB SIGNIFICANTLY LOWERS GLUCOCORTICOID USE AND TOXICITIES IN INDIGO TRIAL
Source text: ID:nGNX571Qg7
Further company coverage: ZBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints